Abstract：
BACKGROUND: Remimazolam, a novel benzodiazepine, shows promise as an alternative to traditional sedatives and hypnotic agents in procedural sedation and general anaesthesia. While preliminary research indicates potential advantages over conventional agents, such as faster onset, predictable duration, and improved safety profile, the extent and quality of existing evidence remain unclear. This scoping review aims to investigate the current clinical role of remimazolam and provide a broad and comprehensive overview.
METHODS: The proposed review will adhere to the JBI methodology for scoping reviews and the Preferred Reporting Items for Systematic Review and Meta-Analysis for Scoping Reviews. A comprehensive search will be conducted across major peer-reviewed databases and grey literature will be sought. All studies involving individuals undergoing procedural sedation or general anaesthesia with remimazolam will be eligible. Data extraction will encompass trial and participant characteristics, intervention details, reported outcomes, comparative efficacy versus midazolam and propofol, patient and operator experience and economic costs.
RESULTS: We will provide a descriptive summary supplemented by statistics, figures and tables where applicable.
CONCLUSIONS: The outlined scoping review aims to assess the clinical use of remimazolam in procedural sedation and as the hypnotic component of general anaesthesia. The review will map the current body of evidence of remimazolam and identify knowledge gaps, contributing to understanding its clinical implications and guiding future research efforts in procedural sedation and general anaesthesia.
METHODS: The proposed review will adhere to the JBI methodology for scoping reviews and the Preferred Reporting Items for Systematic Review and Meta-Analysis for Scoping Reviews. A comprehensive search will be conducted across major peer-reviewed databases and grey literature will be sought. All studies involving individuals undergoing procedural sedation or general anaesthesia with remimazolam will be eligible. Data extraction will encompass trial and participant characteristics, intervention details, reported outcomes, comparative efficacy versus midazolam and propofol, patient and operator experience and economic costs.
RESULTS: We will provide a descriptive summary supplemented by statistics, figures and tables where applicable.
CONCLUSIONS: The outlined scoping review aims to assess the clinical use of remimazolam in procedural sedation and as the hypnotic component of general anaesthesia. The review will map the current body of evidence of remimazolam and identify knowledge gaps, contributing to understanding its clinical implications and guiding future research efforts in procedural sedation and general anaesthesia.
摘要：
背景：雷马唑仑，一种新型苯二氮卓类药物，在程序镇静和全身麻醉中，有望替代传统的镇静剂和催眠药。虽然初步研究表明与常规药物相比具有潜在优势，例如更快的发作，可预测的持续时间，并提高了安全性，现有证据的范围和质量尚不清楚.本范围综述旨在研究瑞米唑仑的当前临床作用，并提供广泛而全面的概述。
方法：建议的审查将遵循JBI方法进行范围审查，以及系统审查和Meta分析的首选报告项目进行范围审查。将在主要的同行评审数据库中进行全面搜索，并寻求灰色文献。所有涉及使用瑞马唑仑进行手术镇静或全身麻醉的个体的研究都是合格的。数据提取将包括试验和参与者特征，干预细节，报告的结果，与咪达唑仑和异丙酚的疗效比较，患者和操作者的经验和经济成本。
结果：我们将提供描述性摘要，并补充统计数据，适用的数字和表格。
结论：概述的范围审查旨在评估瑞马唑仑在手术镇静中的临床应用以及作为全身麻醉的催眠成分。审查将绘制当前的雷马唑仑证据体系，并确定知识差距，有助于理解其临床意义，并指导未来手术镇静和全身麻醉的研究工作。
方法：建议的审查将遵循JBI方法进行范围审查，以及系统审查和Meta分析的首选报告项目进行范围审查。将在主要的同行评审数据库中进行全面搜索，并寻求灰色文献。所有涉及使用瑞马唑仑进行手术镇静或全身麻醉的个体的研究都是合格的。数据提取将包括试验和参与者特征，干预细节，报告的结果，与咪达唑仑和异丙酚的疗效比较，患者和操作者的经验和经济成本。
结果：我们将提供描述性摘要，并补充统计数据，适用的数字和表格。
结论：概述的范围审查旨在评估瑞马唑仑在手术镇静中的临床应用以及作为全身麻醉的催眠成分。审查将绘制当前的雷马唑仑证据体系，并确定知识差距，有助于理解其临床意义，并指导未来手术镇静和全身麻醉的研究工作。
